Methods: We reviewed data generated by ICP-MS and reported by ARUP Laboratories over a period of seven years (2010)(2011)(2012)(2013)(2014)(2015)(2016) for lead, ordered individually (88.2% of total tests) or as a component of the HYMET blood panel (As, Cd, Pb, Hg; 11.8%). Test positivity defined as BLL ≥2 ug/dL, geometric mean of BLL at 95% confidence intervals (CIs), percent BLL results ≥5 ug/dL and ≥10 ug/dL were stratified by age, gender, or geographic location. Additionally, we evaluated data reported for Flint, Michigan, before (2010Michigan, before ( -2013Michigan, before ( ) and after (2015Michigan, before ( -2016 drinking water crisis using similar metrics. Results: The positivity rates of lead testing in children following the CDC switch to 5 ug/dL actionable BLL were 19. 3%-16.8% (2013-2016) compared to 23. 8%-23.2% (2010-2011). Similarly, percent BLL results ≥5 ug/dL and ≥10 ug/dL decreased from 5.5%-6.1% (2010-2011) to 5.6%-5.2% (2013-2016) and 2.1%-2.2% (2010-2011) to 1.9%-1.6% (2013-2016), respectively. The geometric mean of BLL for all populations showed a slight increase over the last seven years, with values ranging from 3.79 ug/dL (2010) to 4.08 ug/dL (2016). In children (≤5 years old) a steady increase from 3.69 ug/dL (2010) to 4.05 ug/dL (2016) was also observed. BLL was higher in men (3.92-4.26 ug/dL) than women (3.61-3.84 ug/dL) with men accounting for 62.8%-68.7% of BLL results ≥5 ug/dL and ≥10 ug/dL, respectively. Finally, the highest percentage of BLL results ≥5 ug/dL and geometric mean BLL (6%, 4.46 ug/dL) for the Flint population was observed in 2014, consistent with the water source switch, compared to 2010-2013 (2.4%-2.1%, 3.07-2.95 ug/dL) and 2015-2016 (3.0%-0.9%, 3.53-3.02 ug/dL).
Background: Graves disease, the most common cause of hyperthyroidism, is defined by the presence of autoantibodies that stimulate the thyroid stimulating hormone receptor (TSHR), resulting in excessive thyroid hormone production. This study evaluated the performance of currently available autoantibody detection methods to aid in the diagnosis of Graves disease, with the goal of bringing in house a method that is most appropriate for our test volume and best clinical practice. Methods: We analyzed 125 patient specimens by three commercially available methods used to assess Graves disease; the Thyretain Thyroid Stimulating Immunoglobulin (TSI) Reporter Bioassay (Bioassay), the TSI Bridge assay by Siemens (Bridge), and the TSHR Antibody (TRAb) assay. Method comparison studies were performed using specimens submitted for TSI measurement in the evaluation of patients suspected of having Graves disease. Based on a Bioassay clinical decision cutoff of ≤1.3, 57 samples had a TSI index <1.3, 22 samples had a TSI index of 1.4-2.5, 24 samples had a TSI index of 2.6-4.8, and 22 samples had a TSI index of ≥4.9. The performance of Bridge and TRAb assays were further evaluated with respect to imprecision, linearity, carryover, and the potential for interference caused by human chorionic gonadotropin (hCG). Discordant results were resolved by reviewing patient history and concurrent thyroid stimulating hormone (TSH), free T4, hCG, and anti-thyroid peroxidase antibody (TPO) results. Results: The TRAb and Bridge assays met manufacturer claims for day-to-day precision, within-run precision, and precision at the clinical decision cutoff. Carryover was also acceptable for both methods. Over a manufacturer-defined analytical measuring range (AMR) of 0.1-40.0 IU/L, the TRAb and Bridge assays were linear up to 20 IU/L and 15 IU/L, respectively. hCG concentrations up to 150,000 mIU/mL did not interfere with any of the three methods. The results obtained by the Siemens TSI assay were most consistent with clinical observations and other laboratory data, whereas inconsistencies were obtained for a larger number of patients with the Bioassay and TRAb methods. Conclusions: Our results show that the Siemens Bridge assay exhibits greater sensitivity than the Bioassay as nine of the 10 "false positives" occurred in patients with a previous positive Bioassay result undergoing treatment for Graves disease. One of the two "false negative" results occurred in a patient with Hashimoto and another with a borderline positive result by the Bioassay. The Roche TRAb assay performed similarly as two of the three "false positive" results were consistent with patient history or concurrent laboratory values, but two "false negative" results could not be explained.
